Skip to main content
. Author manuscript; available in PMC: 2013 Dec 30.
Published in final edited form as: Clin Cancer Res. 2013 Apr 3;19(11):10.1158/1078-0432.CCR-12-3381. doi: 10.1158/1078-0432.CCR-12-3381

Figure 1.

Figure 1

Clinical activity with ganetespib. A, best response in all cohorts. B, Kaplan–Meier curve for PFS in each cohort. C, changes in tumor size in cohort C patients with (n = 8) and without (n = 15) ALK rearrangement. Of all patients in this cohort, the 23 shown had sufficient tissue for assessing ALK gene rearrangement status. D, Kaplan–Meier curve for PFS in patients with (n = 8) versus without (n = 15) ALK rearrangement.